Page 330 - Read Online

Lancaster et al. Vessel Plus 2019;3:34 Vessel Plus
DOI: 10.20517/2574-1209.2019.16

Review Open Access

Surgical treatment for heart failure: cell-based
therapy with engineered tissue

Jordan J. Lancaster , Jen Watson Koevary , Ikeotunye Royal Chinyere , Sherry L. Daugherty ,
1,2
1,3
1,2
1,2
Kenneth A. Fox , Steven Goldman 1,2
4
1 Sarver Heart Center, University of Arizona, Tucson, AZ 85724, United States.
2 Department of Medicine, University of Arizona, Tucson, AZ 85724, United States.
3 Department of Biomedical Engineering, University of Arizona, Tucson, AZ 85724, United States.
4 Department of Surgery, University of Arizona, Tucson, AZ 85724, United States.
Correspondence to: Prof. Jordan J. Lancaster, Sarver Heart Center, University of Arizona, 1501 North Campbell Avenue, Tucson,
AZ 85724, United States. E-mail: Lancaste@email.arizona.edu
How to cite this article: Lancaster JJ, Koevary JW, Chinyere IR, Daugherty SL, Fox KA, Goldman S. Surgical treatment for heart
failure: cell-based therapy with engineered tissue. Vessel Plus 2019;3:34. http://dx.doi.org/10.20517/2574-1209.2019.16

Received: 23 May 2019 First Decision: 3 Jul 2019 Revised: 22 Jul 2019 Accepted: 30 Aug 2019 Published: 17 Sep 2019
Science Editor: Mario F. L. Gaudino Copy Editor: Jia-Jia Meng Production Editor: Jing Yu

Received: First Decision: Revised: Accepted: Published: x
Abstract
Science Editor: Copy Editor: Production Editor: Jing Yu
This review will outline cell-based therapy for heart failure focusing on tissue engineering to deliver cells to the
damaged heart. We will present an overview of the central approaches focusing on pluripotent stem cell-derived
cells, mechanisms of action, autologous vs. allogeneic cell approaches, immunologic modulation, and safety
considerations. We will outline the progress that has been made to-date and define the areas that still need to be
investigated in order to advance the field.

Keywords: Heart failure, induced pluripotent stem cells, tissue engineering

INTRODUCTION
The ability to differentiate specialized functional cells from pluripotent stem cells (PSCs) has opened up
the possibility of new therapeutic approaches that provide the functional units to solve the underlying
causes of disease. Work using cells differentiated from embryonic PSCs first appeared 1998 when Jamie
Thomson and colleagues published a report of deriving embryonic stem cell lines from human blastocyts .
[1]
[2]
This same laboratory described creating induced PSC lines from human somatic cells in 2007 . In 2012,
the Nobel Prize in Physiology or Medicine was awarded to John B. Gurdon and Shinya Yamanaka for

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.vpjournal.net